General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -0.34 | N/A | N/A | N/A |
2024-05-09 | 2024-03 | -0.21 | -0.31 | -0.1 | -47.62% |
2024-03-14 | 2023-12 | 0 | -0.5 | N/A | N/A |
2023-11-09 | 2023-09 | -0.29 | -0.2 | 0.09 | 31.03% |
2023-08-10 | 2023-06 | -0.24 | -0.31 | -0.07 | -29.17% |
2023-05-11 | 2023-03 | -0.23 | -0.2 | 0.03 | 13.04% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-05-14 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-03-19 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-02-22 | HC Wainwright & Co. | Upgrade | Buy | |
2022-11-13 | HC Wainwright & Co. | Upgrade | Buy | |
2022-08-14 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-05-23 | BENSON REED L | General Counsel | 3.17K | Conversion of Exercise of derivative security |
2024-05-22 | BROWN BRIAN LEE | Chief Financial Officer | 290.69K | Stock Award(Grant) |
2024-05-22 | DURENARD EUGENE A | Director | 115.00K | Stock Award(Grant) |
2024-05-22 | EGAN DWIGHT H | Chief Executive Officer | 367.21K | Stock Award(Grant) |
2024-05-22 | MURPHY TED | Director | 127.50K | Stock Award(Grant) |
2024-05-22 | NELSON JAMES B | Director | 115.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.78M | 1.98M | 5.79% |
2023-06-29 | Renaissance Technologies, LLC | 653.70K | 725.61K | 2.12% |
2023-06-29 | Blackrock Inc. | 506.51K | 562.22K | 1.65% |
2023-06-29 | Geode Capital Management, LLC | 302.16K | 335.39K | 0.98% |
2023-06-29 | Bridgeway Capital Management, Inc. | 272.90K | 302.92K | 0.89% |
2023-06-29 | Bank Of New York Mellon Corporation | 145.62K | 161.64K | 0.47% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.28M | 1.42M | 4.15% |
2023-06-29 | Vanguard Extended Market Index Fund | 444.78K | 493.70K | 1.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 272.90K | 302.92K | 0.89% |
2023-05-30 | Fidelity Extended Market Index Fund | 165.22K | 180.09K | 0.54% |
2023-08-30 | iShares Micro Cap ETF | 69.84K | 86.60K | 0.23% |
2023-05-30 | Fidelity Total Market Index Fund | 53.59K | 58.41K | 0.17% |
FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test
by Co-Diagnostics | Mar 17, 2020 | News Release |
Salt Lake City, Utah – March 17, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that a new FDA policy released last night aimed at expediting the availability of COVID-19 diagnostics will allow the Company to aggressively expand its presence in the U.S. market.
Co-Diagnostics was the first U.S. company to obtain a CE marking for a COVID-19 test, and international shipments have continued to escalate. In the past month, the Company has shipped its CE marked and research use Logix Smart COVID-19 test kits to countries all over the world. These include Italy, Germany, the United Kingdom, Turkey, Greece, the Philippines, Thailand, Australia, Paraguay, Ecuador, Israel, South Africa, and Canada, in addition to numerous shipments to customers and research institutions in the United States.
Previous domestic shipments to date have been in accordance with the FDA’s policy change on February 29, 2020 that allows U.S. CLIA laboratories to use the Company’s COVID-19, under certain conditions. Now, as a result of the change announced last night by the FDA, the Company’s test kit will soon be available for use by and marketed to a wide array of U.S. laboratories, without first requiring Emergency Use Authorization.
Co-Diagnostics CEO Dwight Egan remarked “The ramifications of this new FDA policy are significant for our Company. This change will quickly afford Co-Diagnostics even more opportunities to serve the needs of laboratories nationwide, as we play an even larger role in responding to this pandemic. We applaud the FDA’s decision to recognize the dire need for increased access to high-quality COVID-19 tests, and to adapt as the situation demands in light of a public health emergency.
“With no known treatment or approved vaccine for the highly-infectious COVID-19, the need for accurate and rapid diagnoses has never been greater. Our cost-effective Logix Smart CODIV-19 test has been designed to run on a variety of commercially available platforms, with easy-to-interpret results in under two hours. We are confident in our ability to meet the growing demand for this diagnostic.”
See the original press release from the Food and Drug Administration here.
$CODX $MNRA SHIPPED A TEN MINUTE RAPID TEST!
$CODX classic manipulation. This ticker always goes back up.. typically in less than a day. I would suggest patience but how does waiting until AH or the next day even qualify hahaha
WOW start listening at six minutes podcast https://www.smallcapvoice.com/interview-precheck-health-hlty/
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
$CODX FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test https://finance.yahoo.com/news/fda-policy-change-allow-rapid-103000584
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
$CODX I love the random bear comments bashing the stock as it clearly rose 50% in premarket. Yes, yes... $CODX is a scam, no one wants the kits, blah blah blah - and it is not the least bit comical that you have decided to share this vital information and investment advice as our stock is on the path to doubling in less than twenty four hours.
Thanks for the unsolicited and certainly unbiased investment advice bears. Yeah, $CODX was an awful thing to buy yesterday at 8.xx$ and I gravely regret being 50% up day on day.
What a mercy it is that you are here to save my portfolio by saying up is down and black is white.
Time to cover bears. This squeeze will be fun.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
$CODX going to add on the dip after open. Picked up 2250 shares at 8.86 the other day. Every time this goes to single digits I accumulate. Every time it goes over $17 I sell. It’s nuts. Was hoping to add at $6 today and was shocked to see double digits. Will average up I guess on the morning dip / profit taking at open and then hold until above 18$ for half and hold the rest for 21$ then repeat.
Short squeeze may produce an ATH today actually. Bears got very greedy.
$CODX The bears are freaking out. The squeeze should bring us above $20 alone.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.